PATENT CLAIM ANALYSIS

Application Number: 16409092
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-08
Patent Classification: ["514", "019300"]

Abstract:
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Claim (Index 1):
A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence selected from SEQ ID NO: 52, SEQ ID NO: 12, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 36, SEQ ID NO: 42, SEQ ID NO: 96, SEQ ID NO: 165, SEQ ID NO: 16, SEQ ID NO: 176, SEQ ID NO: 2, SEQ ID NO: 5 to SEQ ID NO: 11, SEQ ID NO: 13 to SEQ ID NO: 15, SEQ ID NO: 17 to SEQ ID NO: 35, SEQ ID NO: 37 to SEQ ID NO: 41, SEQ ID NO: 43 to SEQ ID NO: 51, SEQ ID NO: 53 to SEQ ID NO: 95, SEQ ID NO: 97 to SEQ ID NO: 164, SEQ ID NO: 166 to SEQ ID NO: 175, SEQ ID NO: 177 to SEQ ID NO: 198,\n wherein the activated T cells are cytotoxic T cells produced by in vitro contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell, wherein said cancer is selected from the group consisting of acute myelogenous leukemia/acute myeloid leukemia (AML), bile duct cancer, brain cancer, breast cancer, chronic lymphocytic leukemia, colon or rectum cancer, esophageal cancer, gallbladder cancer, liver cancer, melanoma, non-hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, kidney cancer, small cell lung cancer, urinary bladder cancer, and uterine cancer.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 100.0
- Lexical Diversity: 1.61972
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['16359165', '15479552', '15451167', '16192391', '16154457']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8410612675413326
- 35 USC 102 Novelty (BERT): 0.6010309182925265
- Combined Prediction Score: 0.817058232616452
- Mean Citation Score: 603.9459119999998
- Max Citation Score: 622.7216
- Similarity Product: 428.835567053318

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test